Renovorx Inc SEC Filings

RenovoRx, Inc. is launching an at-the-market stock offering of up to $3,723,029 of common shares through JonesTrading. The company may sell shares from time to time, with JonesTrading acting as agent or principal and earning up to a 3% commission on gross proceeds. An illustrative scenario assumes 3,479,466 shares sold at $1.07 per share, which would increase shares outstanding from 36,649,916 to 40,129,382.

RenovoRx plans to use the net proceeds for working capital and general corporate purposes, including its Phase III TIGeR-PaC study of its IAG drug–device combination and commercialization of its FDA-cleared RenovoCath delivery device. The company is a commercial and clinical stage life sciences business focused on targeted intra-arterial chemotherapy using its TAMP platform, and is also running a post-marketing RR5 registry to evaluate RenovoCath in solid tumors.

RenovoRx (RNXT) filed a Form S-3 shelf registration to offer up to $50,000,000 of mixed securities, including common stock, preferred stock, purchase contracts, warrants, subscription rights, depositary shares, debt securities, and units, to be sold from time to time after effectiveness under Rule 415.

Offerings may occur via underwriters, dealers, agents, direct sales, or in at-the-market transactions, with terms and pricing detailed in future prospectus supplements. The company states net proceeds, if and when raised, will support working capital and general corporate purposes, including continued progression of the Phase III TIGeR-PaC study and commercial sales and marketing for the RenovoCath device.

RNXT is listed on Nasdaq Capital Market; the last reported sale price on November 12, 2025 was $1.00 per share. Shares outstanding were 36,649,916 as of November 12, 2025.

RenovoRx (RNXT) furnished an update via an 8-K stating it issued a press release announcing financial results for the quarter ended September 30, 2025. The company also included updates on its clinical trial and commercialization strategy as described in the press release.

The press release is attached as Exhibit 99.1 and incorporated by reference. RNXT’s common stock trades on the Nasdaq Capital Market under the symbol RNXT.

RenovoRx (RNXT) filed its Q3 2025 report, showing early commercial traction and continued losses as it builds out its device-led strategy. Revenue reached $266,000 for the quarter and $885,000 year‑to‑date from RenovoCath sales, producing quarterly gross profit of $213,000.

Operating expenses were $3.4 million, leading to a net loss of $2.9 million for Q3 and $8.2 million for the first nine months. Cash and cash equivalents were $10.0 million as of September 30, 2025, helped by a February underwritten offering that raised $10.8 million in net proceeds. The company reported a common stock warrant liability of $1.11 million and recorded $272,000 of inventory as it scales manufacturing under a supply agreement with $0.7 million in non‑cancellable commitments.

The company concluded current cash will not fund operations for the next 12 months from issuance, indicating a need for additional financing. Shares outstanding were 36,649,916 as of November 12, 2025.

RenovoRx, Inc. director Laurence J. Marton reported a non‑derivative transaction and a derivative grant on 10/01/2025. He was granted 47,640 stock option awards with an exercise price of $1.34, exercisable beginning 10/01/2025 and expiring 10/01/2035. The option shares vest in 12 equal monthly installments starting 11/01/2025. The Form 4 was signed and filed on 10/03/2025. The report lists Mr. Marton as a director and the filing indicates the options are held directly.

RenovoRx director Una S. Ryan was granted a stock option on 10/01/2025 to purchase 47,640 shares of common stock at an exercise price of $1.34 per share. The option vests in 12 equal monthly installments beginning 11/01/2025 and expires on 10/01/2035. Following the grant, Ms. Ryan directly beneficially owns 47,640 options. The Form 4 was signed on 10/02/2025 and shows the filing was made by a single reporting person.

Shaun Bagai, who serves as both Chief Executive Officer and a director of RenovoRx, Inc. (RNXT), reported two open-market purchases of the company's common stock in late August 2025. On 08/22/2025 he acquired 5,000 shares at $0.9495, increasing his beneficial holdings to 325,040 shares. On 08/25/2025 he purchased another 5,000 shares at $0.9098, bringing total reported holdings to 330,040 shares. The Form 4 was signed by Mr. Bagai on 08/26/2025 and expressly states these were open market purchases.

AWM Investment Company, Inc. reports beneficial ownership of 1,870,225 shares of RenovoRx common stock, representing 5.1% of the class. AWM is the investment adviser to three funds that together hold the shares and, as adviser, holds sole voting and dispositive power over the position. The reported holdings break down to 1,064,431 shares held by Special Situations Fund III QP, 296,698 shares held by Special Situations Cayman Fund, and 509,096 shares held by Special Situations Life Sciences Fund.

The filing includes a certification that the securities are held in the ordinary course of business and were not acquired to change or influence control of the issuer.